Ufada A. Nadlifah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ufada A. Nadlifah has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Achmad Z. Arif
Department of Internal Medicine, Karsa Husada General Hospital, Batu, Indonesia
1 shared publicationIwal R. Ahdi
Department of Internal Medicine, Karsa Husada General Hospital, Batu, Indonesia
1 shared publication- Nuril Farid Abshori
Professional Medical Doctor Program, Faculty of Medicine and Health Sciences, Maulana Malik Ibrahim Islamic State University, Malang, Indonesia
1 shared publication - Raihan R. Mardliyyah
Faculty of Medicine and Health Sciences, Maulana Malik Ibrahim Islamic State University Malang, Malang, Indonesia
1 shared publication
Latest Publications
- Open Access
- 3 September 2025
- Published by Narra Sains Indonesia in Narra Review
- Vol. 1 (2) , e10
Effectiveness of mesoporous silica nanoparticle as drug delivery agents for therapeutic improvement of hepatocellular carcinoma: A systematic review
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for approximately 75% of all liver cancer cases, and has the worst prognosis. Current therapies for HCC remain suboptimal, with sorafenib therapy only prolonging survival by 2–3 months, combination therapies often cause adverse events (AEs), and drug resistance remains a challenge. To address these issues, mesoporous silica nanoparticles (MSNs) have been investigated as potential drug delivery systems due to their high surface area, tunable pore size, and ability to enhance drug stability and release. The aim of this study was to explore the potential of MSN-based drug delivery systems for improving HCC therapy. This study employed a systematic review design with a computerized search of six databases up to June 15, 2023. Inclusion criteria were: (1) in vivo studies with mouse subjects, (2) subjects with HCC receiving therapy, (3) therapy conjugated with or coated by MSNs, and (4) evaluation of therapeutic effectiveness based on statistical outcomes. Exclusion criteria included irrelevant titles or abstracts, incomplete texts, and non-original research such as reviews, case reports, and conference abstracts. A total of 1,844 studies were screened, and eight studies met the eligibility criteria for analysis. The results indicated that MSN-based drug delivery systems significantly improved therapeutic outcomes in HCC-bearing mice by enhancing drug penetration, reducing tumor size, and minimizing systemic toxicity compared to conventional formulations. These findings suggest that MSNs hold promise as an advanced drug delivery platform for HCC therapy. However, further preclinical and clinical studies are required before translation into clinical practice.
- 3 September 2025
- Published by Narra Sains Indonesia in Narra Review
- Vol. 1 (2) , e10
Open AccessEffectiveness of mesoporous silica nanoparticle as drug delivery agents for therapeutic improvement of hepatocellular carcinoma: A systematic review
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for approximately 75% of all liver cancer cases, and has the worst prognosis. Current therapies for HCC remain suboptimal, with sorafenib therapy only prolonging survival by 2–3 months, combination therapies often cause adverse events (AEs), and drug resistance remains a challenge. To address these issues, mesoporous silica nanoparticles (MSNs) have been investigated as potential drug delivery systems due to their high surface area, tunable pore size, and ability to enhance drug stability and release. The aim of this study was to explore the potential of MSN-based drug delivery systems for improving HCC therapy. This study employed a systematic review design with a computerized search of six databases up to June 15, 2023. Inclusion criteria were: (1) in vivo studies with mouse subjects, (2) subjects with HCC receiving therapy, (3) therapy conjugated with or coated by MSNs, and (4) evaluation of therapeutic effectiveness based on statistical outcomes. Exclusion criteria included irrelevant titles or abstracts, incomplete texts, and non-original research such as reviews, case reports, and conference abstracts. A total of 1,844 studies were screened, and eight studies met the eligibility criteria for analysis. The results indicated that MSN-based drug delivery systems significantly improved therapeutic outcomes in HCC-bearing mice by enhancing drug penetration, reducing tumor size, and minimizing systemic toxicity compared to conventional formulations. These findings suggest that MSNs hold promise as an advanced drug delivery platform for HCC therapy. However, further preclinical and clinical studies are required before translation into clinical practice.